Palisade Bio (NasdaqCM:PALI) FY Conference Transcript

Summary of Palisade Bio FY Conference Call Company Overview - Company: Palisade Bio (NasdaqCM:PALI) - Industry: Biotechnology, specifically focusing on oral therapeutics in the Inflammatory and Immune (I&I) space - Lead Drug: PALI-2108, a PDE4 inhibitor developed for treating inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis [2][3] Core Points and Arguments - Drug Development Background: - PALI-2108 was originally developed by Merck and later reformulated as a prodrug by Giiant Pharma [2] - The prodrug formulation is crucial as it mitigates severe adverse events associated with traditional PDE4 inhibitors, such as secretory diarrhea and CNS events [3][4] - Clinical Development Status: - Completed preclinical development and initiated clinical trials, treating 84 healthy volunteers and 5 ulcerative colitis patients [4][5] - Currently conducting a small cohort study in fibrostenotic Crohn's disease, with results expected by the end of the month [5] - Plans to file an IND for a definitive study in ulcerative colitis involving 196 patients by May, with patient treatment starting in early Q3 2026 and data readout by the end of 2027 [5][13] - Market Potential: - Crohn's disease and ulcerative colitis are multi-billion dollar markets, with fibrostenotic Crohn's disease being a significant unmet need as there are currently no approved therapies [14] - The company aims to differentiate itself with a dual-acting anti-inflammatory and anti-fibrotic drug, which is unique in the market [11][19] - Competitive Landscape: - Competitors include Agomab, which recently IPO'd at over $750 million, and other PDE4 inhibitors like AstraZeneca's roflumilast and Amgen's Otezla [12][14] - The company has developed a precision medicine test to identify potential responders to PALI-2108 [12] - Efficacy and Safety Data: - Early data from a phase 1B study showed promising results, including a 63% improvement in the modified Mayo score and significant reductions in inflammatory markers after just one week of treatment [24][42] - The drug demonstrated good safety and tolerability, with no serious adverse events reported even at high doses [44][45] Additional Important Content - Financial Position: - Completed a financing round in October 2025, providing sufficient funds to support definitive studies in both ulcerative colitis and fibrostenotic Crohn's disease, with a runway extending into 2029 [30][31] - Team and Expertise: - The company has built a strong team with experience from major pharmaceutical companies, enhancing its capability to execute its development plans [32] - Regulatory Considerations: - The company is evaluating whether to pursue a broader indication for Crohn's disease or focus specifically on fibrosing Crohn's, depending on the data from ongoing studies [33][34] - Market Positioning: - The company aims to position PALI-2108 as a faster-acting oral option in a market currently dominated by injectable therapies with lower remission rates [40][41] - Long-term Durability of Response: - The company is confident in the long-term efficacy of PALI-2108 based on historical data from other PDE4 inhibitors and ongoing studies [42][43] This summary encapsulates the key points discussed during the Palisade Bio FY Conference Call, highlighting the company's strategic direction, clinical development progress, market potential, and competitive landscape.